Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471058 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL2262870 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL19364082 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL470721 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL471721 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL14805424 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL509424 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL7876216 | 0.84 | BTK (0.51) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL18766144 | 0.82 | BTK (0.54) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL17398093 | 0.81 | BTK (0.56) | BTKGAACTSKKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022048631-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| US-8158658-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1670478-A4 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | UNIV NORTHWESTERN (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090104677-A1 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-20090104677-A1 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-7470790-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470790-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1670478-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-19 | — | — | US | disclosed |
| WO-2005026111-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | BTK 4472/4885GAA 375/4885CTSK 2588/4885 |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | BTK 1274/4885GAA 2633/4885CTSK 4219/4885 |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | BTK 3996/4885GAA 552/4885CTSK 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.